Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Distal jejunal-release dextrose (Aphaia Technology) in obese subjects
2020-005989-34Phase 2Completed
- Sponsor
- Aphaia Pharma
- Start
- Apr 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and 3 more comparing Aphaia Technology distal jejunal-release dextrose with Placebo (2 arms). Primary endpoint: Percent weight loss at 6 months vs placebo. Started Apr 2022; status: completed.
02
Drugs
dextrose
03
Conditions
obesitymetabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)hypertension (HTN)Endocrinopathy
Beyond the preview
Go deeper on 2020-005989-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005989-34.